NCT04216329 2026-01-23
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT03367572 2025-09-25
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Phase 3 Completed
NCT04503668 2025-06-18
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
University of Michigan Rogel Cancer Center
Phase 3 Terminated
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02939287 2024-10-22
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
Phase 3 Completed
NCT03137121 2021-08-17
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
University of Alabama at Birmingham
Phase 2/3 Completed
NCT02635984 2018-08-20
FOND-O
Augusta University
Phase 3 Completed
NCT00910988 2018-07-18
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Washington University School of Medicine
Phase NA Completed